Simona Halep Doping: The International Tennis Integrity Agency (ITIA) announced on Friday that Simona Halep, a former world number one, has been provisionally suspended for doping. According to a statement from the ITIA, Halep’s sample from the US Open revealed residues of Roxadustat, a medication used to treat renal disease patients that increases the creation of red blood cells.
ITIA in their statement said that, “The subsequent analysis found that the A sample contiained FG-4592 (Roxadustat), which is a prohibited substance listed in the 2022 World Anti-Doping Agency (WADA) Prohibited List. Adverse Analytical Findings for non-specified substances carry a mandatory provisional suspension. The player exercised their right to request that the B sample was analysed, which confirmed the finding in the A sample. While provisionally suspended, the player is ineligble to compete in or attend any sanctioned tennis events organised by the governing bodies of the sport.”
Also Read: Manchester United: Things going wrong for Ronaldo? Star player dropped for the match against Chelsea
However, after receiving a temporary suspension for doping, Halep stated that she would “fight till the end” to demonstrate that she had not taken an illegal drug with knowledge.
The International Tennis Integrity Agency (ITIA) said that a sample Halep submitted during the US Open in August included residues of Roxadustat, a medication that increases the production of red blood cells and is used to treat patients with renal issues. The nine-ranked Halep described the positive result as “the worst shock in my life.”
“Throughout my whole career, the idea of cheating never even crossed my mind once, as it is totally against all the values I have been educated with,” Halep said in a statement.
“I will fight until the end to prove that I never knowingly took any prohibited substance and I have faith that sooner or later, the truth will come out.”
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.
